Intercept Sank 40% in September following Dear Doctor and FDA warning letters; Ritu Baral weighs in.
Analyst praises Alnylam’s patisiran as best-in-class, even more confident in its safety and tolerability profile.
Ritu Baral sees 35% upside for Aldeyra on back of positive Phase 2a dry eye study.
Analyst upbeat on boosted dystrophin expression levels in Sarepta’s lead candidate golodirsen.
Insmed’s lead asset ALIS poses compelling prospects for commercial success in the U.S., says top analyst.
Gilead is very confident on the successful commercial launch of Axi-Cel.
Gilead Pivots to Cell Therapy; Cowen’s Phil Nadeau Weighs in
Cowen Sees Light at the End of the Tunnel for Ultragenyx Following a Failed Phase 3 Study in GNEM
It is a nice time to be a Myokardia Inc (NASDAQ:MYOK) investor, particularly on back …
Genocea Biosciences Inc (NASDAQ:GNCA) shares were plummeting almost 15% yesterday after the biotech firm and …